UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q

(MARK  ONE)

[X]     QUARTERLY  REPORT  PURSUANT  TO  SECTION  13  OR 15(D) OF THE SECURITIES
        EXCHANGE  ACT  OF  1934

        FOR  THE  QUARTERLY  PERIOD  ENDED  SEPTEMBER  30,  1999  OR

[  ]    TRANSITION  REPORT  PURSUANT  TO  SECTION 13 OR 15(D) OF THE SECURITIES
        EXCHANGE  ACT  OF  1934
        FOR  THE  TRANSITION  PERIOD  FROM  _______  TO  _________

COMMISSION  FILE  NUMBER  0-17139

                                   GENUS, INC.
             (Exact name of registrant as specified in its charter)

     CALIFORNIA     94-279080
     (State  or  other  jurisdiction  of     (I.R.S.  Employer
     incorporation  or  organization)     Identification  No.)

     1139  KARLSTAD  DRIVE,  SUNNYVALE,  CALIFORNIA     94089
     (Address  of  principal  executive  offices)     (Zip  code)

                                 (408) 747-7120
              (Registrant's telephone number, including area code)

                                 NOT APPLICABLE
    (Former name, former address and former fiscal year, if changed since last
                                     report)

Indicate by check mark whether the registrant (1) has filed all reports required
to  be  filed  by  Sections  13  or 15(d) of the Securities Exchange Act of 1934
during  the  preceding  12  months  (or  for such period that the registrant was
required  to  file  such  reports),  and  (2)  has  been  subject to such filing
requirements  for  the  past  90  days.  Yes  X  No
                                             --

Indicate  the  number  of  shares outstanding of each of the issuer's classes of
common  stock,  as  of  the  latest  practicable  date:

Common  shares  outstanding  at  November  8,  1999:        18,281,897
                                                         ----------------

<PAGE>

                         PART I.  FINANCIAL INFORMATION


ITEM  1.  FINANCIAL  STATEMENTS

<TABLE>
<CAPTION>
                                           GENUS, INC. AND SUBSIDIARIES
                                       CONSOLIDATED STATEMENTS OF OPERATIONS
                                                    (UNAUDITED)

                                   (AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

                                                         THREE MONTHS ENDED      NINE MONTHS ENDED
                                                           SEPTEMBER 30,           SEPTEMBER 30,
                                                     ------------------------  --------------------
                                                          1999        1998        1999      1998
                                                     -----------  -----------  ---------  ---------
<S>                                                  <C>          <C>          <C>        <C>
Net sales                                            $     8,818  $    9,804   $ 22,736   $ 27,312

Costs and expenses:
  Cost of sales                                            5,021       5,889     13,120     22,554
  Research and development                                 1,474       1,517      4,018      7,788
  Selling, general and administrative                      2,072       2,347      5,954     12,253
  Special charge                                               0           0          0     13,216
                                                     -----------  -----------  ---------  ---------
    Income (loss) from operations                            251          51       (356)   (28,499)

Other, net                                                    62         (11)       237       (404)
                                                     -----------  -----------  ---------  ---------
  Net income (loss)                                          313          40       (119)   (28,903)

Deemed dividends on preferred stock                            0           0          0     (1,903)
                                                     -----------  -----------  ---------  ---------

Net income (loss) available to common shareholders   $       313  $       40   $   (119)  $(30,806)
                                                     ===========  ===========  =========  =========

Basic and diluted net income (loss) available to
common shareholders per common share and
per common share assuming dilution                   $      0.02  $     0.00   $  (0.01)  $  (1.79)
                                                     ===========  ===========  =========  =========

Shares used in per share calculation
Basic shares                                              18,267      17,361     18,083     17,216
                                                     ===========  ===========  =========  =========
Diluted shares                                            18,943      17,413     18,083     17,216
                                                     ===========  ===========  =========  =========
<FN>

The  accompanying  notes  are  an  integral  part  of  these  financial  statements.
</TABLE>

<PAGE>
<TABLE>
<CAPTION>
                                  GENUS, INC. AND SUBSIDIARIES
                                   CONSOLIDATED BALANCE SHEETS
                                           (UNAUDITED)

                          (AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

                                                        SEPTEMBER 30, 1999    DECEMBER 31, 1998
                                                       --------------------  -------------------
<S>                                                    <C>                   <C>
ASSETS
Current assets:
  Cash and cash equivalents                            $             5,534   $            8,125
  Accounts receivable (net of allowance for doubtful
  accounts of $499 in 1999 and $500 in 1998)                        12,081               13,008
  Inventories                                                        5,561                5,338
  Other current assets                                                 418                  379
                                                       --------------------  -------------------
    Total current assets                                            23,594               26,850

  Property and equipment, net                                        4,496                4,659
  Other assets, net                                                    332                  318
                                                       --------------------  -------------------
    Total assets                                       $            28,422   $           31,827
                                                       ====================  ===================

LIABILITIES
Current liabilities:
  Short-term bank borrowings                           $                 0   $            4,000
  Accounts payable                                                   3,767                2,193
  Accrued expenses                                                   3,870                4,908
                                                       --------------------  -------------------
    Total current liabilities                                        7,637               11,101
                                                       --------------------  -------------------

Redeemable Series B Convertible Preferred
Stock, no par value:
  Authorized 28,000 shares;
  Issued and outstanding, none (1999) and
  16,000 shares (1998), liquidation preference,
  none (1999) and $50 per share (1998)                                   0                  773
                                                       --------------------  -------------------

SHAREHOLDERS' EQUITY
Common stock, no par value:
  Authorized 50,000,000 shares;
  Issued and outstanding 18,281,897 shares at
  September 30, 1999 and 17,361,162 shares at
  December 31, 1998                                                100,787               99,849
Accumulated deficit                                                (78,374)             (78,255)
Accumulated other comprehensive loss                                (1,628)              (1,641)
                                                       --------------------  -------------------
  Total shareholders' equity                                        20,785               19,953
                                                       --------------------  -------------------
    Total liabilities, redeemable preferred stock,
    and shareholders' equity                           $            28,422   $           31,827
                                                       ====================  ===================
<FN>

The  accompanying  notes  are  an  integral  part  of  these  financial  statements.
</TABLE>

<PAGE>
<TABLE>
<CAPTION>
                                 GENUS, INC. AND SUBSIDIARIES
                             CONSOLIDATED STATEMENTS OF CASH FLOWS
                                          (UNAUDITED)

                         (AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

                                                                   NINE MONTHS ENDED
                                                                     SEPTEMBER 30,
                                                                ----------------------
                                                                    1999        1998
                                                                -----------  ---------
<S>                                                             <C>          <C>
Cash flows from operating activities:
  Net loss                                                      $     (119)  $(28,903)
  Adjustments to reconcile net income (loss)
  to net cash from operating activities:
    Depreciation and amortization                                    1,327      2,315
    Special charge                                                       0     13,216
    Changes in assets and liabilities:
      Accounts receivable                                              927      9,027
      Inventories                                                     (223)    (1,721)
      Other assets                                                     (53)       721
      Accounts payable                                               1,574     (7,340)
      Accrued expenses                                              (1,038)    (3,966)
      Other, net                                                         0       (643)
                                                                -----------  ---------
        Net cash provided by (used in) operating activities          2,395    (17,294)
                                                                -----------  ---------

Cash flows from investing activities:
  Acquisition of property and equipment                             (1,164)      (442)
  Sales of Ion Technology Products                                       0     23,150
                                                                -----------  ---------
    Net cash used in investing activities                           (1,164)    22,708
                                                                -----------  ---------

Cash flows from financing activities:
  Proceeds from issuance of common stock                               165        120
  Proceeds from issuance of preferred stock and warrants, net            0      4,816
  Redemption of preferred stock                                          0     (4,725)
  Payments of short-term bank borrowings                            (4,000)    (7,200)
  Payments of long-term debt                                             0       (870)
                                                                -----------  ---------
    Net cash provided by (used in) financing activities             (3,835)    (7,859)
                                                                -----------  ---------

Effect of exchange rate changes on cash                                 13        153
                                                                -----------  ---------

Net increase (decrease) in cash and cash equivalents                (2,591)    (2,292)
Cash and cash equivalents, beginning of period                       8,125      8,700
                                                                -----------  ---------
Cash and cash equivalents, end of period                        $    5,534   $  6,408
                                                                ===========  =========
<FN>

The  accompanying  notes  are  an  integral  part  of  these  financial  statements.
</TABLE>

<PAGE>
                          GENUS, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                         SEPTEMBER 30, 1999 (UNAUDITED)

Basis  of  Presentation

The  accompanying  consolidated  financial  statements  have  been  prepared  in
accordance  with  SEC  requirements  for  interim  financial  statements.  These
financial  statements  should  be  read  in  conjunction  with  the consolidated
financial  statements  and  notes  thereto included in the Company's 1998 Annual
Report  on  Form  10-K.

The  information  furnished  reflects all adjustments (consisting only of normal
recurring  adjustments)  which  are, in the opinion of management, necessary for
the  fair  statement of financial position, results of operations and cash flows
for  the  interim  periods.  The  results  of operations for the interim periods
presented  are not necessarily indicative of results to be expected for the full
year.

Net  Income  (Loss)  Per  Share

Basic  net  income  (loss)  per  share  is  computed  by  dividing income (loss)
available to common shareholders by the weighted average number of common shares
outstanding  for  the period. Diluted net income (loss) per share is computed by
dividing  income  (loss)  available  to  common  shareholders,  adjusted  for
convertible  preferred  dividends  and after-tax interest expense on convertible
debt,  if  any,  by  the  sum  of  the  weighted average number of common shares
outstanding  and  potential  common  shares  (when  dilutive).

<PAGE>
                          GENUS, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                         SEPTEMBER 30, 1999 (UNAUDITED)

A  reconciliation  of  the  numerator  and  denominator of basic and diluted net
income  (loss)  per  share  is  as  follows:

<TABLE>
<CAPTION>
                                  (AMOUNTS  IN  THOUSANDS,  EXCEPT  PER  SHARE  DATA)

                                            THREE MONTHS ENDED     NINE MONTHS ENDED
                                                SEPTEMBER 30,         SEPTEMBER 30,
                                         -----------------------  -------------------
                                             1999        1998       1999      1998
                                         -----------  ----------  --------  ---------
<S>                                      <C>          <C>         <C>       <C>

Numerator-basic:
  Net income (loss)                      $       313  $       40  $  (119)  $(28,903)
  Deemed dividends on preferred stock              0           0        0     (1,903)
                                         -----------  ----------  --------  ---------
    Net income (loss) available to
    common shareholders                  $       313  $       40  $  (119)  $(30,806)
                                         ===========  ==========  ========  =========

Denominator-basic:
  Weighted average common shares
  outstanding                                 18,267      17,361   18,083     17,216
                                         ===========  ==========  ========  =========

Basic net income (loss) per share        $      0.02  $     0.00  $ (0.01)  $  (1.79)
                                         ===========  ==========  ========  =========

Numerator-diluted:
  Net income (loss)                      $       313  $       40  $  (119)  $(28,903)
  Deemed dividends on preferred stock              0           0        0     (1,903)
                                         -----------  ----------  --------  ---------
    Net income (loss) available to
    common shareholders                  $       313  $       40  $  (119)  $(30,806)
                                         ===========  ==========  ========  =========

Denominator-diluted:
  Weighted average common shares
  outstanding                                 18,267      17,361   18,083     17,216
  Effect of dilutive securities: stock
  options                                        676          52        0          0
                                         -----------  ----------  --------  ---------
                                              18,943      17,413   18,083     17,216
                                         ===========  ==========  ========  =========

Diluted net income (loss) per share      $      0.02  $     0.00  $ (0.01)  $  (1.79)
                                         ===========  ==========  ========  =========
</TABLE>

<PAGE>
                          GENUS, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                         SEPTEMBER 30, 1999 (UNAUDITED)

Stock  options  to  purchase approximately 2,189,122 shares of common stock were
outstanding  during  the  nine  months  ended  September  30,  1999 but were not
included  in the computation of diluted income per share because the Company has
a  net  loss  for the nine months ended September 30, 1999. Warrants to purchase
400,000  shares  of  common  stock were outstanding during the nine months ended
September  30,  1999  but were not included in the computation of diluted income
per share because the Company has a net loss for the nine months ended September
30,  1999.

Stock  options  to  purchase approximately 1,856,043 shares of common stock were
outstanding  during  the  nine  months  ended  September  30,  1998 but were not
included  in the computation of diluted loss per share because the Company has a
net  loss  for  the  nine  months  ended  September  30,  1998.

<TABLE>
<CAPTION>
Statement  of  Cash  Flow  Information

                                                  (AMOUNTS  IN  THOUSANDS)

                                                        NINE MONTHS ENDED
                                                           SEPTEMBER 30,
                                                       -------------------
                                                         1999       1998
                                                       --------    -------
<S>                                                    <C>          <C>
Supplemental Cash Flow Information:

  Cash paid during the period for:
    Interest                                           $      0     $  183
    Income taxes                                              0          1

  Non-cash financing activities:
    Deemed dividends on preferred stock related
      to beneficial conversion feature                 $      0     $1,903
    Conversion of Series A Convertible Preferred
      Stock to common stock                                   0        124
</TABLE>

Line  of  Credit

The  Company's  secured  Accounts  Receivable  Purchase  Agreement  expired  on
September  30, 1999.  The Company is in the process of negotiating a $10 million
revolving  line  of  credit with Venture Bank that will provide the Company with
any  required short-term funding, as well as the liquidity to support the future
growth  expected  in  2000 and beyond.  It is expected that the line will have a
maturity  of  2 years, and be based on 80% of eligible accounts receivable, with
an  interest  rate  of  prime  plus  0.25%.

<PAGE>
                          GENUS, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                         SEPTEMBER 30, 1999 (UNAUDITED)

                             (AMOUNTS IN THOUSANDS)

<TABLE>
<CAPTION>

INVENTORIES
Inventories  comprise  the  following:

                          SEPTEMBER 30,   DECEMBER 31,
                              1999           1998
                         --------------  -------------
<S>                      <C>             <C>

Raw materials and parts  $        4,849  $       5,094
Work in process                     712            244
                         --------------  -------------
                         $        5,561  $       5,338
                         ==============  =============
</TABLE>

<TABLE>
<CAPTION>

ACCRUED  EXPENSES
Accrued  expenses  comprise  the  following:

                                     SEPTEMBER 30,   DECEMBER 31,
                                         1999           1998
                                    --------------  -------------
<S>                                 <C>             <C>

System installation and warranty    $          870  $         583
Accrued commissions and incentives             395            538
Accrued payroll and related items              545            536
Restructuring reserves                         263          1,240
Income taxes                                   456            456
Other                                        1,609          1,555
                                    --------------  -------------
                                    $        4,138  $       4,908
                                    ==============  =============
</TABLE>


In  1998,  the  Company  recorded  a  special  charge  of approximately $12,707.
Included in this special charge were personnel charges of $1,746 associated with
the Company's reduction in workforce as well as $5,400 in inventory write-downs,
and  $1,113  in  leasehold  improvement  write-offs.  In  addition,  this charge
included  $1,402  for  expenses  associated  with  the  closing of several sales
offices  and  transaction  losses  as  a  result  of the sale of the ion implant
products to Varian Associates, Inc. ("Varian") and $1,053 for legal, accounting,
and  banking  fees  associated with the Varian transaction. Finally, the special
charge  included a $1,993 write-off of ion implant inventory that is currently a
matter of dispute with Varian in connection with the Asset Sale. The Company and
Varian  are  in  the  process  of  resolving  the dispute through arbitration to
determine  whether the Company or Varian has rights to this ion implant sale and
related  inventory.  If the Company prevails in the arbitration, any adjustments
to  the  Company's financial statements will be made in the quarter in which the
decision  is  rendered and the collection of the amount in question is probable.
The  Company  is  not  conceding  any  rights  to  the  disputed  sale.

During  the  third quarter of 1999, $597 of payroll, legal and transaction costs
were  charged  against  the  restructuring  reserve.

At  September  30,  1999,  the following components of the restructuring reserve
associated  with  the  special  charge  remain  unpaid:  $141  in  payroll costs
associated  with  the  reduction  in  force  and  $122 in transaction costs. The
Company  expects  these  amounts  to be paid by the end of the fourth quarter of
1999.

<PAGE>
                          GENUS, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                         SEPTEMBER 30, 1999 (UNAUDITED)

ISSUANCE  OF  PREFERRED  STOCK  AND  WARRANTS

Warrants

In  connection  with  the  issuance  of the Series A Convertible Preferred Stock
(Series  A  Stock),  the  Company  issued  warrants  for  400,000  shares of the
Company's  common  stock  to the holders of the Series A Stock. The warrants are
exercisable  at  any time until February 2001 for 300,000 shares of common stock
at  a  price  of  $3.67 per share and for 100,000 shares at a price of $4.50 per
share.

LEGAL  PROCEEDINGS

The Company and Varian Associates, Inc. (Varian) are in the process of resolving
a  dispute  through arbitration as required by the Asset Purchase Agreement. The
original  dispute was in regard to whether Genus or Varian has rights to one ion
implant  sale and inventory. Subsequently, Genus also made claims against Varian
with  respect  to  the  earnout provision in the Asset Purchase Agreement, which
requires  Varian to pay Genus one-third of all revenue recorded in excess of $30
million during calendar year 1998. Varian then expanded its claim to include two
other  ion  implant  shipments  that  Varian  contends  did  not  meet  revenue
recognition requirements. These two systems, valued at $7 million, were recorded
as revenue by Genus prior to the closing of the Asset Purchase Agreement. If the
Company  prevails in the arbitration, any adjustments to the Company's financial
statements will be made in the quarter in which the decision is rendered and the
collection  of  the amount in question is probable. The Company is not conceding
any  rights  to  the  disputed  sales  and  believes that it will prevail in the
arbitration.

The  Company  has  been  named as a defendant in a claim involving an automobile
accident  by a former employee of the Company, which resulted in the death of an
individual.  General,  punitive,  and  exemplary damages are being sought by the
plaintiffs.  The  Company  believes  it  is not at fault in this matter, and has
appointed  legal  council  to  defend  the  claim.

<PAGE>
                          GENUS, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                         SEPTEMBER 30, 1999 (UNAUDITED)

COMPREHENSIVE  INCOME

Statement  of  Financial  Accounting  Standards  No.  130 (SFAS 130), "Reporting
Comprehensive  Income"  establishes  rules  for  the  reporting  and  display of
comprehensive  income  and  its  components.

The  following  are  the  components  of  comprehensive  loss:

<TABLE>
<CAPTION>

          (AMOUNTS  IN  THOUSANDS)

                                             THREE MONTHS ENDED     NINE MONTHS ENDED
                                                SEPTEMBER 30,         SEPTEMBER 30,
                                           ---------------------  ---------------------
                                               1999       1998       1999       1998
                                           ----------  ---------  ---------  ----------
<S>                                        <C>         <C>        <C>        <C>

Net income (loss)                          $      313  $      40   $   (119)  $(30,806)
Foreign currency translation adjustments           52        (82)        13      2,255
                                           ----------  ----------  ---------  ---------
  Comprehensive income (loss)              $      365  $     (42)  $   (106)  $(28,551)
                                           ==========  ==========  =========  =========
</TABLE>

The components of accumulated other comprehensive income, net of related tax are
as  follows:

<TABLE>
<CAPTION>

                                        (AMOUNTS  IN  THOUSANDS)

                                     SEPTEMBER 30    DECEMBER 31
                                         1999           1998
                                    --------------  -------------
<S>                                 <C>             <C>

Cumulative translation adjustments  $      (1,628)  $     (1,641)
                                    ==============  =============
</TABLE>

<PAGE>

ITEM  2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF  OPERATIONS

Statements in this report which express "belief", anticipation" or "expectation"
as  well  as  other statements which are not historical fact are forward-looking
statements  within  the meaning of Section 27A of the Securities Act of 1933 and
Section  21E  of  the  Securities  Exchange  Act  of 1934. These forward-looking
statements  are  subject  to  certain  risks  and uncertainties that could cause
actual  results  to  differ  materially  from  historical results or anticipated
results,  including  those  set forth under "Risk Factors" in this "Management's
Discussion  and  Analysis  of Financial Condition and Results of Operations" and
elsewhere  in  or  incorporated  by  reference  into  this report. The following
discussion should be read in conjunction with the Company's Financial Statements
and  Notes  thereto  included  in  this  report.

Results  of  Operations

Net  sales  for  the  three  and  nine months ended September 30, 1999 were $8.8
million  and  $22.7 million, respectively, compared to net sales of $9.8 million
and  $27.3  million  for  the  corresponding  periods  in  1998,  which included
shipments  of  both  ion implant and thin film products. Revenue for the current
quarter  included thin film system shipments to Asia, while approximately 50% of
the  revenue  from  the  quarter  ending September 30, 1998 was from ion implant
products.  Quarterly  thin  film  revenue  has  doubled over the past 12 months.
Year-to-date  thin  film  revenue  is  more  than  three  times greater than the
year-to-date  1998  figures.

Gross  margin for the three and nine months ended September 30, 1999 was 43% and
42%,  respectively,  compared to 40% and 17% for the same periods in 1998. Fixed
operations  and  service  overhead  costs  remained  flat  throughout  1999, and
variable  material  and  warranty  costs have been consistent as a percentage of
sales. In 1998, the Company was structured to support much higher revenue levels
than  were  achieved.  This  resulted  in  a  severe  underabsorption  of  fixed
operations and service overhead expenses. During the second quarter of 1998, the
Company  implemented cost reduction measures which significantly decreased these
fixed  overhead  expenses. The Company believes that the current organization is
more  properly sized to achieve reasonable gross margins going forward, assuming
revenue  targets  are  met.

Research  and development expenses (R&D) for the third quarter of 1999 were $1.5
million, or 17% of sales, compared to $1.5 million reported in the third quarter
of  1998.  R&D  spending  for the first three quarters of 1999 was $4.0 million,
compared to $7.8 million during the first three quarters of 1998. This reduction
was primarily attributed to R&D expenses associated with the ion implant product
line  which  was  sold  to  Varian in July of 1998. The Company expects spending
levels  to  remain  consistent for 1999. In July of 1999, the Company introduced
its RInG  (Rapidly Integrated Gate) product, which increases the access speed of
the  DRAM, and ALD (Atomic Layer Deposition) product, which can deposit films an
order  of  magnitude  thinner  than  current  technology.

Selling,  General  and  Administrative expenses (SG&A) were $2.1 million for the
third  quarter of 1999, a decrease of $275,000 from the $2.3 million of SG&A for
the  third  quarter  of  1998.  Year-to-date  SG&A  expenses  were $5.9 million,
compared to $12.3 million for 1998. The expense reductions were related to costs
associated  with the ion implant product line, and a $1.4 million write-off of a
receivable  from  Innotech  Corporation,  formerly  the  Company's  Japanese
distributor,  during  the  second  quarter  of 1998. SG&A expenses for the third
quarter  of  1999  were higher than the previous quarter due to costs associated
with  the  successful  implementation of the Company's new ERP system, BAAN, and
other  Y2K compliance expenses on October 1, 1999. The Company believes that the
major  internal  Y2K  issues  have  now  been  addressed.

For  the  third  quarter  of  1999,  other income was $62,000, compared to other
expense of $11,000 in the third quarter of 1998. For the first three quarters of
1999,  other  income  was  $237,000,  while  other  expense  for the first three
quarters of 1998 was $404,000.  Other income consists mainly of interest income,
while  other expense for 1998 included interest expenses associated with capital
leases,  short-term  borrowings  and  foreign  exchange  losses.

The net income for the quarter ended September 30, 1999 was $313,000 compared to
net  income of $40,000 for the third quarter of 1998. The net loss for the first
nine  months of 1999 was $119,000, compared to net loss of $30.8 million for the
same  period  in  1998.  Included  in  the first nine months of 1998 was a $13.2
million  special  charge  for costs associated with reorganizing the Company and
selling  the  ion  implant  product line to Varian, and deemed dividends of $1.9
million  on the $5 million worth of Series A Convertible Preferred Stock, all of
which  has  been  retired.

Liquidity  and  Capital  Resources

During  the  three  months ended September 30, 1999, the Company's cash and cash
equivalents were $5.5 million compared to $8.1 million at December 31, 1998. The
Company collected $6 million of outstanding receivables during the third quarter
of 1999. Two systems, which shipped during the second quarter and were valued at
$5  million, were given extended payment terms and are scheduled to be collected
in  December  of  1999. Total cash collected in 1999 was $20.5 million. Accounts
receivable  was  $12.1 million at September 30, 1999, compared to $13 million at
December  31,  1998. Several systems that shipped with extended payment terms in
1998  were  collected  during the first nine months of 1999. The current balance
includes  third  quarter  shipments  valued  at  $6.5 million and second quarter
shipments  with  extended  payment  terms  valued  at  $5  million.

Operating  activities.  Operating  activities  provided cash of $2.4 million for
the  nine  month period ended September 30, 1999, compared to cash used of $17.3
million for the corresponding period ended September 30, 1998. The cash provided
by  operating  activities  for  the  nine month period ended September 30, 1999,
consisted  of a net decrease in working capital of $1.2 million and depreciation
and  amortization of $1.3 million, partially offset by our net loss of $119,000.
The  cash  used  in operating activities for the nine months ended September 30,
1998,  consisted  of  a  net  loss  of  $28.9 million and an increase in working
capital  of  $3.9  million, partially offset by depreciation and amortization of
$2.3 million and a special charge of $13.2 million. Accounts receivable declined
by  $927,000  for the nine-month period ended September 30, 1999, compared to an
increase  of  $9  million  for the same period of 1998. The decrease in accounts
receivable  compared  to the increase in the prior year is due to lower sales in
1999  compared  to  1998, offset by the accounts receivable balance at September
30,  1999,  which  included two systems with extended payment terms. Inventories
decreased  by  $223,000  in  the  nine-month  period  ended  September 30, 1999,
compared  to a decrease of $1.7 million in the prior year due to the shipment of
a  thin  film  system  to  Samsung  in the third quarter of 1998, which had been
originally  scheduled  to  ship  in  the  fourth  quarter  of 1997. The material
required  to build this system was purchased in 1997. Accounts payable increased
by $1.6 million in the nine-month period ended September 30, 1999, compared to a
decrease  of  $7.3  million in the same period in 1998. The increase in accounts
payable  in  1999 was due to an increase in inventory purchases during the third
quarter,  and  not processing vendor checks during the last 2 weeks of September
due  to the Company's conversion to a new ERP system, BAAN. The decrease in 1998
accounts  payable was primarily due to final payments made to ion implant vendor
accounts  with proceeds from the Asset Sale to Varian. Accrued expenses declined
$1  million  in  the  nine-month  period ended September 30, 1999, compared to a
decrease  of $4 million in the same period in 1998. The 1999 decrease was due to
charges  against the restructuring reserve, and the 1998 reduction was primarily
due  to  the  transfer  of warranty and installation reserves related to the ion
implant  product  line  to  Varian  as  part  of the Asset Sale in July of 1998.

Investing  activities.  Investing  activities  used cash of $1.2 million for the
nine-month  period ended September 30, 1999. For the nine months ended September
30,  1999,  investing  activities  provided  cash  of  $22.7  million.  Capital
expenditures  were  $1.2  million for the current nine-month period, compared to
$442,000  for  the  same  period  of  1998. The increase in capital expenditures
related  primarily  to  demo  system  upgrades,  the  new  ERP system, and other
computer  related purchases. We anticipate an additional $250,000 to $500,000 in
capital  expenditures  before  the  end  of  1999.

Financing  activities. Financing activities used cash of $3.8 million during the
nine  months  ended  September  30,  1999.  This was primarily related to the $4
million  repayment of the short-term bank borrowings offset by $165,000 from the
proceeds  of the employee stock purchase plan and the exercise of employee stock
options.

The  Company  believes that its existing working capital and cash generated from
operations  will  be  sufficient  to  satisfy  its  cash  needs  going  forward.
Currently,  cash  not  required for operating purposes is invested in short-term
money  market  funds.  There  can  be  no assurance that any required additional
funding,  if needed, will be available on terms attractive to the Company, which
could  have  a  material  adverse  effect  on  the Company's business, financial
condition,  and  results  of  operations. Any additional equity financing may be
dilutive  to  shareholders,  and  debt  financing,  if  available,  may  involve
restrictive  covenants.

Risk  Factors

Certain sections of Management's Discussion and Analysis contain forward-looking
statements  within  the meaning of Section 27A of the Securities Act of 1933, as
amended,  and  Section  21E  of the Securities Exchange Act of 1934, as amended.
Actual  results  could  differ  materially  from  those  projected  in  the
forward-looking  statements  as  a  result  of  the  factors  set forth above in
Management's  Discussion  and  Analysis  and  this  Risk  Factors  section.  The
discussion  of  these  factors  is  incorporated  by  this  reference as if said
discussion  was  fully  set  forth  in  Management's  Discussion  and  Analysis.

Historical  Performance.  The  Company  has experienced losses of $29.5 million,
$19.3  million, and $9.2 million for the years ended December 31, 1998, 1997 and
1996,  respectively. In addition, the Company experienced a net loss of $119,000
in  the  first  nine months of 1999. As a result of the Company's volatile sales
and  operating  results  in  recent  years,  there  can be no assurance that the
Company  will be able to attain or sustain consistent future revenue growth on a
quarterly  or  annual  basis,  or  that  the  Company  will be able to attain or
maintain  consistent  profitability  on  a  quarterly  or  annual  basis.

Reliance  on  International Sales. Export sales accounted for approximately 56%,
74%  and  84%  of  total  net  sales  in  the  years  ended 1998, 1997 and 1996,
respectively.  In  addition,  net  sales to South Korean customers accounted for
approximately 34%, 50% and 59%, respectively, of total net sales during the same
periods. In the first nine months of 1999, export sales to South Korea accounted
for approximately 86% of total sales, including 98% in the first quarter, 70% in
the  second  quarter  and 95% in the third quarter. The Company anticipates that
sales  to  one  customer  in  Korea  will  continue to account for a significant
portion  of net sales. As a result, a significant portion of the Company's sales
will  be  subject  to  certain risks, including unexpected changes in regulatory
requirements,  tariffs  and  other barriers, political and economic instability,
difficulties  in  accounts  receivable  collection,  difficulties  in  managing
distributors  or  representatives, difficulties in staffing and managing foreign
subsidiary  operations  and  potentially  adverse tax consequences. Although the
Company's foreign system sales are primarily denominated in U.S. dollars and the
Company does not engage in hedging transactions, the Company's foreign sales are
subject to the risks associated with unexpected changes in exchange rates, which
could  have  the effect of making the Company's products more or less expensive.
There  can  be  no  assurance that any of these factors will not have a material
adverse  effect  on  the  Company's business, financial condition and results of
operations.

Further,  the  Company  has  a  wholly  owned  South Korean subsidiary providing
service  and  support  to  the  installed base of customers and whose functional
currency  is  the won. There can be no assurance that the Company will not incur
currency  losses  or  gains  in  future  quarters  as  the  currency fluctuates.

A  substantial portion of the Company's sales is in Asia, bringing certain risks
to  the Company. Currency devaluation may make dollar-denominated goods, such as
the  Company's,  more expensive for Asian clients. Asian manufacturers may limit
capital  spending.  Furthermore,  the  uncertainty  of the DRAM market may cause
manufacturers  everywhere  to  delay capital spending plans. These circumstances
may  also  affect  the  ability  of  Company  customers  to  meet  their payment
obligations,  resulting in the cancellations or deferrals of existing orders and
the  limitation  of  additional  orders. Such developments could have a material
adverse  effect  on  the  Company's business, financial condition and results of
operations.

Reliance  on  a  Small  Number  of  Customers  and Concentration of Credit Risk.
Historically,  the  Company  has  relied  on a limited number of customers for a
substantial  portion  of  its  net  sales.  In  1998,  three  customers, Samsung
Electronics  Company,  Ltd.,  M/A Com and SGS Thomson, accounted for 68%, 8% and
5%,  respectively, of the Company's thin films net sales. During the first three
quarters  of  1999, Samsung accounted for 85% of sales. For the first quarter of
1999,  Samsung  accounted  for  98%  of  total sales, during the second quarter,
Samsung  and  a  new  U.S.  customer accounted for 80% and 14%, respectively, of
total  sales,  and  during the third quarter, Samsung accounted for 88% of total
sales.  Additionally,  Samsung  accounted  for an aggregate of 90% of thin films
accounts  receivable  at  December  31,  1998.  Because  the  semiconductor
manufacturing  industry  is concentrated in a limited number of generally larger
companies,  the Company expects that a significant portion of its future product
sales  will  be concentrated within a limited number of customers. None of these
customers  has  entered  into a long-term agreement requiring it to purchase the
Company's  products.  Furthermore,  sales  to  certain  of  these  customers may
decrease in the future when those customers complete their current semiconductor
equipment  purchasing  requirements  for new or expanded fabrication facilities.
The loss of a significant customer or any reduction in orders from a significant
customer,  including  reductions  due  to customer departures from recent buying
patterns,  market,  economic  or  competitive  conditions  in  the semiconductor
industry  or  in  the  industries that manufacture products utilizing ICs, could
have  a  material  adverse effect on the Company's business, financial condition
and  results  of  operations.

The  Company  is  dependent  on  a  small  number of customers. Accordingly, the
Company  is subject to concentration of credit risk. If a major customer were to
encounter  financial difficulties and become unable to meet its obligations, the
Company  would  be  adversely  impacted.

Cyclical  Nature  of  the Semiconductor Industry. The Company's business depends
upon  the  capital  expenditures  of  semiconductor manufacturers, which in turn
depend  on  the  current  and  anticipated  market  demand  for ICs and products
utilizing  ICs.  The semiconductor industry is cyclical and experiences periodic
downturns,  which  have an adverse effect on the semiconductor industry's demand
for  semiconductor  manufacturing  capital  equipment.  Semiconductor  industry
downturns  have adversely affected the Company's revenues, operating margins and
results of operations. There can be no assurance that the Company's revenues and
operating  results  will not continue to be materially and adversely affected by
future  downturns  in  the  semiconductor  industry.  In  addition, the need for
continued  investment  in  R&D,  substantial  capital equipment requirements and
extensive  ongoing  worldwide customer service and support capability limits the
Company's  ability  to  reduce expenses. Accordingly, there is no assurance that
the  Company  will  be  able  to  attain  profitability  in  the  future.

Fluctuations in Quarterly Operating Results. The Company's revenue and operating
results may fluctuate significantly from quarter-to-quarter. The Company derives
its  revenue primarily from the sale of a relatively small number of high-priced
systems,  many  of which may be ordered and shipped during the same quarter. The
Company's  results  of  operations  for  a particular quarter could be adversely
affected  if  anticipated  orders,  for even a small number of systems, were not
received  in  time  to enable shipment during the quarter, anticipated shipments
were  delayed or canceled by one or more customers or shipments were delayed due
to  manufacturing  difficulties. The Company's revenue and operating results may
also  fluctuate due to the mix of products sold and the channel of distribution.

Competition.  The  semiconductor  manufacturing  capital  equipment  industry is
highly  competitive.  Genus  faces substantial competition throughout the world.
The  Company  believes  that  to remain competitive, it will require significant
financial  resources  in order to offer a broader range of products, to maintain
customer service and support centers worldwide and invest in product and process
R&D. Many of the Company's existing and potential competitors have substantially
greater  financial  resources,  more  extensive  engineering,  manufacturing,
marketing and customer service and support capabilities, as well as greater name
recognition than the Company. The Company expects its competitors to continue to
improve  the  design and performance of their current products and processes and
to  introduce  new  products  and  processes with improved price and performance
characteristics. If the Company's competitors enter into strategic relationships
with  leading semiconductor manufacturers covering thin film products similar to
those  sold  by  the Company, it would materially adversely effect the Company's
ability  to  sell its products to these manufacturers. There can be no assurance
that  the  Company will continue to compete successfully in the United States or
worldwide.  The  Company  faces  direct competition in Chemical Vapor Deposition
(CVD)  tungsten silicide (WSiX) from Applied Materials, Inc. and Tokyo Electron,
Ltd.  In  addition,  the  Company  faces  direct  competition  in  Atomic  Layer
Deposition (ALD) with ASM International. There can be no assurance that these or
other  competitors  will  not  succeed  in developing new technologies, offering
products  at  lower  prices  than  those  of  the  Company  or  obtaining market
acceptance  for  products  more  rapidly  than  the  Company.

Dependence  on  New Products and Processes. The Company believes that its future
performance  will  depend  in  part  upon its ability to continue to enhance its
existing  products and their process capabilities and to develop and manufacture
new  products  with  improved  process  capabilities.  As  a result, the Company
expects  to  continue  to  invest  in  R&D. The Company also must manage product
transitions  successfully,  as  introductions  of  new  products could adversely
effect  sales  of  existing  products. There can be no assurance that the market
will  accept  the  Company's  new  products  or that the Company will be able to
develop  and introduce new products or enhancements to its existing products and
processes  in  a  timely  manner  to  satisfy  customer  needs or achieve market
acceptance.  The  failure  to  do so could have a material adverse effect on the
Company's  business, financial condition and results of operations. Furthermore,
if  the  Company  is  not successful in the development of advanced processes or
equipment  for  manufacturers  with  whom it has formed strategic alliances, its
ability to sell its products to those manufacturers would be adversely affected.

Product  Concentration;  Rapid Technological Change. Semiconductor manufacturing
equipment  and  processes are subject to rapid technological change. The Company
derives its revenue primarily from the sale of its WSiX CVD systems. The Company
estimates  that  the  life  cycle  for  these systems is generally three to five
years.  The  Company believes that its future prospects will depend in part upon
its  ability  to  continue  to  enhance  its existing products and their process
capabilities  and  to develop and manufacture new products with improved process
capabilities.  As  a result, the Company expects to continue to make significant
investments  in  R&D.  The  Company  also  must  manage  product  transitions
successfully,  as  introductions of new products could adversely effect sales of
existing products. There can be no assurance that future technologies, processes
or product developments will not render the Company's product offerings obsolete
or  that  the  Company  will  be  able  to develop and introduce new products or
enhancements  to its existing and future processes in a timely manner to satisfy
customer  needs  or  achieve  market  acceptance.  The  failure  to  do so could
adversely  effect  the  Company's  business,  financial condition and results of
operations.  Furthermore, if the Company is not successful in the development of
advanced  processes  or  equipment for manufacturers with whom it currently does
business,  its  ability  to  sell  its  products to those manufacturers would be
adversely  affected.

Dependence  on  Patents and Proprietary Rights. The Company's success depends in
part  on  its  proprietary technology. While the Company attempts to protect its
proprietary  technology through patents, copyrights and trade secret protection,
it  believes  that  the success of the Company will depend on more technological
expertise,  continuing  the  development  of new systems, market penetration and
growth  of  its  installed base and the ability to provide comprehensive support
and  service  to  customers.  There can be no assurance that the Company will be
able  to  protect its technology or that competitors will not be able to develop
similar  technology  independently. The Company currently has a number of United
States  and  foreign  patents and patent applications. There can be no assurance
that  any  patents  issued to the Company will not be challenged, invalidated or
circumvented  or  that  the  rights  granted thereunder will provide competitive
advantages  to  the  Company.

From  time-to-time, the Company has received notices from third parties alleging
infringement  of  such parties' patent rights by the Company's products. In such
cases, it is the policy of the Company to defend against the claims or negotiate
licenses on commercially reasonable terms where considered appropriate. However,
no  assurance  can be given that the Company will be able to negotiate necessary
licenses  on  commercially  reasonable  terms, or at all, or that any litigation
resulting  from  such  claims  would  not  have a material adverse effect on the
Company's  business  and  financial  results.

Dependence  on  Key  Suppliers.  Certain  of  the  components and sub-assemblies
included  in  the  Company's  products  are obtained from a single supplier or a
limited  group  of  suppliers.  Disruption or termination of these sources could
have  a  temporary  adverse  effect  on  the  Company's  operations. The Company
believes  that  alternative  sources  could  be obtained and qualified to supply
these  products,  if  necessary.  Nevertheless,  a prolonged inability to obtain
certain  components  could  have  a  material  adverse  effect  on the Company's
business,  financial  condition  and  results  of  operations.

Dependence on Independent Distributors. The Company currently sells and supports
its  thin  film products through direct sales and customer support organizations
in  the  U.S.,  Western  Europe  and  South  Korea  and through seven exclusive,
independent  sales  representatives and distributors in the U.S., Europe, Japan,
South Korea, Taiwan, China and Malaysia. The Company does not have any long-term
contracts  with its sales representatives and distributors. Although the Company
believes  that alternative sources of distribution are available, the disruption
or  termination of its existing distributor relationships could have a temporary
adverse  effect  on  the  Company's business, financial condition and results of
operations.

Volatility  of  Stock  Price.  The  Company's  common  stock  has  experienced
substantial  price  volatility,  particularly  as a result of quarter-to-quarter
variations  in  the actual or anticipated financial results of, or announcements
by,  the  Company,  its  competitors  or  its  customers,  announcements  of
technological  innovations  or  new  products by the Company or its competitors,
changes  in  earnings  estimates  by  securities  analysts  and  other events or
factors.  Also,  the  stock  market  has  experienced  extreme  price and volume
fluctuations  which have affected the market price of many technology companies,
in  particular, and which have often been unrelated to the operating performance
of these companies. These broad market fluctuations, as well as general economic
and  political  conditions  in  the United States and the countries in which the
Company  does  business,  may adversely effect the market price of the Company's
Common  Stock.  In  addition,  the  occurrence of any of the events described in
these  "Risk Factors" could have a material adverse effect on such market price.

Readiness  for  Year  2000. Many existing computer systems and applications, and
other control devices, use only two digits to identify a year in the date field,
without  considering  the  impact  of  the upcoming change in the century. These
computer  systems and applications could fail or create erroneous results unless
corrected  so  that  they can process data related to the Year 2000. The Company
relies  on its systems, applications and devices in operating and monitoring all
major  aspects  of  its  business,  including financial systems (such as general
ledger, accounts payable and payroll modules), customer service, infrastructure,
embedded  computer  chips,  networks  and  telecommunications  equipment and end
products.  The  Company  also relies on external systems of business enterprises
such  as  customers,  suppliers,  creditors,  financial  organizations,  and  of
governments  both  domestically  and globally, directly for accurate exchange of
data  and  indirectly.

The  Company  has  nearly completed its Year 2000 readiness project, and most of
the mission critical issues have already been closed. The director of operations
and facilities chairs the project team and it includes project managers from the
finance,  information  technology, facilities, engineering, and customer support
organizations.  The  team meets regularly, and has conducted a thorough analysis
to  identify  systems  that  will possibly be impacted by the Year 2000 problem.
These systems have been classified into four major segments: facilities, mission
critical  business  operations systems, non-mission critical business operations
systems  and  general office equipment. The project team has assigned one of its
members  to  be  the project manager for each segment, and each of these segment
project  managers  has  identified  an  implementation  manager  for each system
identified as part of their segment. Each implementation manager has developed a
detailed  plan  that includes an assessment of Year 2000 compliance, followed by
phases  to  define a contingency plan, evaluate alternatives, select a solution,
design  and  implement the solution and, finally, to test and verify compliance.
Some  of  the  critical systems already addressed are discussed in the following
paragraphs.

End  Products.  The  control  systems  for  each  of  the Company's products are
computer  driven.  Thorough testing of these products was completed during 1998.
Testing addressed not only the Company designed elements of the system, but also
the  embedded  controls  in  manufactured  components  integrated  into  the end
products.  Each  product  requires a software upgrade, and the oldest systems in
the  product  line  require  a  control system computer replacement as well. The
Company  is charging a nominal amount for these upgrades on the older generation
systems,  while  upgrades  for  the  current  Lynx2  products are supplied at no
charge.  The  design  and  testing  of  each of these product upgrades have been
completed,  and  the  upgrades  have  been  shipped and installed at some of the
Company's customer's sites worldwide. The Company has contacted and offered this
upgrade  to all of its customers, but some customers have decided not to upgrade
their  systems. The Company is in the process of securing a written release from
customers  who  have  decided  not  to  purchase the upgrade for their installed
systems.

Enterprise  Resources  Program.  The  Company's  Year 2000 project plan included
implementation  of  a  new Baan enterprise resources program system. The cutover
from  the  existing system to the new system was completed October 1, 1999.  The
Company  is  still  working through minor implementation follow-up items, but is
effectively  running  operations  with the new system. The Baan product has been
certified  as  Year  2000  compliant,  and this product is running at many major
manufacturing  companies  worldwide.  The  system  was considered to be the most
critical  internal  Company resource at risk to the Year 2000 problem, so timely
implementation  was  essential.

Supplier Readiness. Each implementation manager is responsible for assessing the
readiness  of the suppliers who support their systems to ensure there will be no
lapses  in  service  that  may  interrupt  operations.  This  is  in addition to
addressing  readiness  of  the  hardware and software products provided by these
suppliers. The Company started surveying suppliers of inventory material for the
Company's  products  during  the  second  quarter  of  1999.  This is one of the
projects  under  the  mission  critical  business  operations  systems  segment.
Readiness  of the supplier's products has already been established under the end
product project, but addressing potential disruptions of the supply pipeline due
to supplier business readiness is on-going.  The Company has yet to identify any
key  suppliers  who  are  not  diligently  ensuring  their  Y2K  readiness.

Computer  Resources.  All  of the Company's computer network resources have been
upgraded in the last nine months to ensure Year 2000 compatibility. As with most
businesses  today,  these  resources have become essential communications tools,
both  internal  and  external  to  the Company, making their continued operation
mission  critical. The effort to upgrade client computer resources (notebook and
desktop  personal  computers)  is  on-going,  with  completion  of  all upgrades
expected  by  December  1,  1999.

The  Company's  estimated  expenses  incurred  through  December  31,  1998  are
$300,000.  The  1999  projected  costs  are $350,000, of which $320,000 has been
incurred  so  far. The Company believes that costs to fix the Company's products
have  already been fully incurred. Several capital investments have already been
made  in  1999  to replace aging equipment, and Year 2000 compliant systems were
purchased  in  all  cases.  This  includes  new network and electronic mail file
servers.  The  Company's  voicemail  system  was  not  Year  2000 compliant, but
replacement  is  complete.  There  are a few more hardware and software systems,
both  mission  critical  and non-mission critical, which may require upgrades at
the  Company's  expense  during  the  fourth  quarter, but preliminary estimates
indicate these expenses will not be material. There can be no assurance that the
Company's  current  estimated  costs associated with the Year 2000 issue, or the
consequences  of  incomplete or untimely resolution of the Year 2000 issue, will
not  have  a  material  adverse  effect on the result of operations or financial
position  of  the  Company  in  any  given  year.

The  Company  has not yet identified any specific contingency plans in the event
that  projects  are not completed in time or if planned fixes fail to operate as
expected.  Each  implementation  project  manager  is responsible for completing
contingency  plans  for  assigned  projects  as  part  of  the planning process.

At  this  time, the Company does not plan to use any outside agencies to provide
independent  verification  of  readiness,  although  individual  implementation
project managers may decide to include independent verification as part of their
project  plans.  The  independent  verification requirement will be based on the
risk  associated  with  failure of the particular project/system. The Company is
setting  up  a program to use in-house quality system auditors to perform audits
of  some  of  the  critical  projects  to provide some independent assessment of
readiness.

<PAGE>
                           PART II.  OTHER INFORMATION


ITEM  6.  EXHIBITS  AND  REPORTS  ON  FORM  8-K

(a)       Exhibits

The  Exhibits  listed  on the accompanying "Index to Exhibits" are filed as part
hereof,  or  incorporated  by  reference  into,  the  report.

<PAGE>
                                   GENUS, INC.

                                   SIGNATURES


Pursuant  to  the  requirements  of  the  Securities  Exchange  Act of 1934, the
Registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  thereunto  duly  authorized.





Date:  November  15,  1999                      GENUS,  INC.




                                                 /s/  William W.R. Elder
                                            ------------------------------------
                                                William W.R. Elder, President,
                                            Chief Executive Officer and Chairman




                                                  /s/  Kenneth Schwanda
                                             -----------------------------------
                                                       Kenneth Schwanda
                                                    Chief Financial Officer
                                              (Principal Financial and Principal
                                                      Accounting Officer)

<PAGE>

               GENUS, INC.
           INDEX TO EXHIBITS


EXHIBIT NO.  DESCRIPTION
-----------  ---------------------------


27.1         Financial Data Schedule

<PAGE>